Share Price and Basic Stock Data
Last Updated: January 23, 2026, 4:54 pm
| PEG Ratio | -30.81 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Ipca Laboratories Ltd operates in the pharmaceuticals sector, providing a diverse portfolio of products including formulations and active pharmaceutical ingredients (APIs). The company has demonstrated robust revenue growth, with reported sales rising to ₹6,204 Cr for FY 2023, up from ₹5,797 Cr in FY 2022. The latest quarterly data shows further momentum, with sales reaching ₹2,034 Cr in September 2023 and ₹2,053 Cr in December 2023. This upward trajectory is indicative of a strong demand for its products, particularly in both domestic and international markets. The trailing twelve months (TTM) revenue stood at ₹9,357 Cr, reflecting a substantial increase compared to previous years. The company’s focus on expanding its product lines and entering new markets has contributed significantly to this growth, positioning it favorably against industry norms. The pharmaceutical sector in India is expected to grow at a CAGR of 11.3% from 2021 to 2026, according to the Indian Brand Equity Foundation (IBEF), further supporting Ipca’s growth potential.
Profitability and Efficiency Metrics
Ipca Laboratories has reported a net profit of ₹854 Cr for FY 2025, with an earnings per share (EPS) of ₹35.14, which reflects an increase from ₹32.78 in the previous year. The company’s operating profit margin (OPM) stood at 19% for FY 2025, indicating efficient cost management and operational effectiveness. The operating profit for the latest quarter of September 2025 was ₹545 Cr, maintaining a consistent margin of 21% over the last quarter. Furthermore, the interest coverage ratio (ICR) is notably strong at 21.42x, showcasing the company’s ability to meet its interest obligations comfortably. However, the return on equity (ROE) at 12.8% and return on capital employed (ROCE) at 14.7% reflect moderate profitability compared to sector averages, suggesting room for improvement in utilizing equity and capital for generating returns. In terms of cash generation, the cash EPS for FY 2025 was ₹46.72, which supports operational liquidity.
Balance Sheet Strength and Financial Ratios
As of September 2025, Ipca Laboratories reported total assets of ₹12,263 Cr, with total liabilities amounting to ₹12,263 Cr. The company holds reserves of ₹7,402 Cr, showcasing a solid equity base that supports its financial stability. The long-term debt to equity ratio is low at 0.07, indicating a conservative approach to leveraging. Meanwhile, the current ratio of 2.63 and quick ratio of 1.55 signal robust liquidity positions, ensuring that the company can meet short-term obligations. However, the total debt to equity ratio at 0.18 suggests that while the company is not heavily leveraged, it does have some debt exposure. The price-to-book value (P/BV) ratio of 5.48x indicates that the stock may be trading at a premium relative to its book value, which could imply investor confidence but also raises concerns about overvaluation. The company’s financial structure appears sound, but maintaining balance between growth and financial prudence will be essential.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Ipca Laboratories reflects a diverse ownership structure, with promoters holding 44.72% of the company as of September 2025. Institutional investors, including foreign institutional investors (FIIs) and domestic institutional investors (DIIs), hold 10.42% and 36.45% respectively, indicating significant institutional confidence in the company. The public shareholding stands at 8.09%, with the total number of shareholders reported at 82,870. This diversified ownership base can be a strength, as it may reduce volatility and enhance corporate governance. However, the decline in promoter holding from 46.29% in December 2022 to 44.72% could raise concerns about management’s long-term commitment to the company. The relatively stable institutional holdings suggest that larger investors are optimistic about the company’s future, which can bolster market sentiment. The consistent dividend payout, with a ratio of 13.75% for FY 2025, further reflects management’s commitment to returning value to shareholders.
Outlook, Risks, and Final Insight
Ipca Laboratories is well-positioned for growth, driven by strong revenue trends and a solid balance sheet. However, it faces challenges including regulatory pressures and market competition, particularly in the global pharmaceutical space. The company’s ability to innovate and expand its product offerings will be crucial in maintaining its competitive edge. Additionally, fluctuations in raw material costs and foreign exchange rates could impact profitability margins. On the positive side, the company’s strong operational efficiency and robust financial ratios provide a solid foundation for navigating these challenges. If Ipca can leverage its strengths in R&D and maintain its focus on quality and compliance, it may enhance its market position. Conversely, any deterioration in market conditions or adverse regulatory changes could pose risks to its growth trajectory. Overall, while uncertainties exist, the fundamentals suggest a promising outlook for Ipca Laboratories in the evolving pharmaceutical landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 123 Cr. | 98.0 | 203/84.3 | 27.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,696 Cr. | 340 | 479/192 | 76.5 | 24.3 | 0.20 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.3 Cr. | 43.5 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 61.0 Cr. | 41.6 | 42.0/17.0 | 145 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,555.91 Cr | 1,088.51 | 47.87 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,601 | 1,546 | 1,512 | 1,585 | 2,034 | 2,053 | 2,033 | 2,093 | 2,355 | 2,245 | 2,247 | 2,309 | 2,556 |
| Expenses | 1,341 | 1,330 | 1,331 | 1,278 | 1,673 | 1,722 | 1,711 | 1,700 | 1,913 | 1,782 | 1,818 | 1,892 | 2,012 |
| Operating Profit | 260 | 216 | 181 | 308 | 361 | 331 | 322 | 393 | 441 | 463 | 429 | 416 | 545 |
| OPM % | 16% | 14% | 12% | 19% | 18% | 16% | 16% | 19% | 19% | 21% | 19% | 18% | 21% |
| Other Income | 36 | 31 | 36 | 45 | -1 | 91 | -118 | 21 | 26 | 20 | -179 | 33 | -30 |
| Interest | 9 | 11 | 18 | 31 | 44 | 33 | 29 | 24 | 23 | 17 | 22 | 19 | 20 |
| Depreciation | 64 | 67 | 70 | 69 | 90 | 100 | 98 | 99 | 100 | 98 | 100 | 100 | 103 |
| Profit before tax | 223 | 169 | 129 | 252 | 225 | 289 | 77 | 290 | 345 | 368 | 128 | 331 | 392 |
| Tax % | 35% | 32% | 37% | 34% | 39% | 23% | 96% | 31% | 29% | 25% | 49% | 29% | 28% |
| Net Profit | 146 | 110 | 78 | 164 | 136 | 221 | 1 | 199 | 246 | 276 | 64 | 233 | 281 |
| EPS in Rs | 5.67 | 4.25 | 3.02 | 6.42 | 5.72 | 7.09 | 2.35 | 7.58 | 9.05 | 9.78 | 2.67 | 9.19 | 11.14 |
Last Updated: January 1, 2026, 6:16 am
Below is a detailed analysis of the quarterly data for Ipca Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 2,556.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,309.00 Cr. (Jun 2025) to 2,556.00 Cr., marking an increase of 247.00 Cr..
- For Expenses, as of Sep 2025, the value is 2,012.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,892.00 Cr. (Jun 2025) to 2,012.00 Cr., marking an increase of 120.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 545.00 Cr.. The value appears strong and on an upward trend. It has increased from 416.00 Cr. (Jun 2025) to 545.00 Cr., marking an increase of 129.00 Cr..
- For OPM %, as of Sep 2025, the value is 21.00%. The value appears strong and on an upward trend. It has increased from 18.00% (Jun 2025) to 21.00%, marking an increase of 3.00%.
- For Other Income, as of Sep 2025, the value is -30.00 Cr.. The value appears to be declining and may need further review. It has decreased from 33.00 Cr. (Jun 2025) to -30.00 Cr., marking a decrease of 63.00 Cr..
- For Interest, as of Sep 2025, the value is 20.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 19.00 Cr. (Jun 2025) to 20.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 103.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 100.00 Cr. (Jun 2025) to 103.00 Cr., marking an increase of 3.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 392.00 Cr.. The value appears strong and on an upward trend. It has increased from 331.00 Cr. (Jun 2025) to 392.00 Cr., marking an increase of 61.00 Cr..
- For Tax %, as of Sep 2025, the value is 28.00%. The value appears to be improving (decreasing) as expected. It has decreased from 29.00% (Jun 2025) to 28.00%, marking a decrease of 1.00%.
- For Net Profit, as of Sep 2025, the value is 281.00 Cr.. The value appears strong and on an upward trend. It has increased from 233.00 Cr. (Jun 2025) to 281.00 Cr., marking an increase of 48.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 11.14. The value appears strong and on an upward trend. It has increased from 9.19 (Jun 2025) to 11.14, marking an increase of 1.95.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:10 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,282 | 3,144 | 2,867 | 3,156 | 3,258 | 3,746 | 4,619 | 5,395 | 5,797 | 6,204 | 7,662 | 8,897 | 9,357 |
| Expenses | 2,539 | 2,604 | 2,573 | 2,705 | 2,803 | 3,051 | 3,715 | 3,843 | 4,472 | 5,272 | 6,338 | 7,166 | 7,504 |
| Operating Profit | 743 | 541 | 294 | 451 | 455 | 695 | 904 | 1,552 | 1,325 | 932 | 1,324 | 1,731 | 1,853 |
| OPM % | 23% | 17% | 10% | 14% | 14% | 19% | 20% | 29% | 23% | 15% | 17% | 19% | 20% |
| Other Income | 21 | 32 | 21 | 11 | 41 | 56 | 65 | 59 | 54 | 123 | 17 | -114 | -157 |
| Interest | 30 | 32 | 35 | 27 | 28 | 22 | 20 | 12 | 11 | 48 | 141 | 88 | 76 |
| Depreciation | 103 | 180 | 163 | 173 | 178 | 182 | 210 | 209 | 232 | 262 | 357 | 398 | 402 |
| Profit before tax | 631 | 361 | 117 | 262 | 291 | 546 | 739 | 1,389 | 1,136 | 745 | 843 | 1,131 | 1,218 |
| Tax % | 24% | 28% | 18% | 26% | 18% | 19% | 18% | 17% | 20% | 34% | 37% | 30% | |
| Net Profit | 479 | 254 | 93 | 195 | 239 | 442 | 604 | 1,141 | 890 | 479 | 523 | 785 | 854 |
| EPS in Rs | 18.96 | 10.07 | 3.69 | 7.71 | 9.49 | 17.60 | 23.99 | 44.94 | 34.85 | 18.58 | 21.57 | 29.08 | 32.78 |
| Dividend Payout % | 13% | 5% | 0% | 6% | 5% | 9% | 10% | 9% | 11% | 22% | 19% | 14% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -46.97% | -63.39% | 109.68% | 22.56% | 84.94% | 36.65% | 88.91% | -22.00% | -46.18% | 9.19% | 50.10% |
| Change in YoY Net Profit Growth (%) | 0.00% | -16.41% | 173.06% | -87.11% | 62.37% | -48.29% | 52.26% | -110.91% | -24.18% | 55.37% | 40.91% |
Ipca Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 14% |
| 3 Years: | 15% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 7% |
| 3 Years: | -1% |
| TTM: | 44% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 6% |
| 3 Years: | 15% |
| 1 Year: | -7% |
| Return on Equity | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 14% |
| 3 Years: | 10% |
| Last Year: | 13% |
Last Updated: September 5, 2025, 7:50 am
Balance Sheet
Last Updated: December 4, 2025, 1:27 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
| Reserves | 1,934 | 2,183 | 2,234 | 2,430 | 2,663 | 3,097 | 3,602 | 4,676 | 5,439 | 5,817 | 6,307 | 6,923 | 7,402 |
| Borrowings | 603 | 935 | 867 | 716 | 628 | 465 | 501 | 265 | 807 | 1,481 | 1,438 | 1,363 | 1,279 |
| Other Liabilities | 648 | 669 | 765 | 788 | 799 | 961 | 1,130 | 1,099 | 1,349 | 1,300 | 3,326 | 3,432 | 3,557 |
| Total Liabilities | 3,211 | 3,812 | 3,892 | 3,960 | 4,116 | 4,549 | 5,258 | 6,066 | 7,622 | 8,623 | 11,097 | 11,744 | 12,263 |
| Fixed Assets | 1,354 | 1,800 | 2,014 | 1,983 | 1,953 | 1,940 | 2,059 | 2,072 | 2,402 | 2,751 | 4,554 | 4,267 | 4,371 |
| CWIP | 165 | 267 | 129 | 95 | 73 | 66 | 133 | 235 | 306 | 140 | 343 | 622 | 777 |
| Investments | 9 | 16 | 26 | 136 | 87 | 120 | 310 | 505 | 989 | 626 | 862 | 980 | 1,203 |
| Other Assets | 1,683 | 1,729 | 1,723 | 1,746 | 2,003 | 2,422 | 2,756 | 3,254 | 3,924 | 5,105 | 5,339 | 5,875 | 5,912 |
| Total Assets | 3,211 | 3,812 | 3,892 | 3,960 | 4,116 | 4,549 | 5,258 | 6,066 | 7,622 | 8,623 | 11,097 | 11,744 | 12,263 |
Below is a detailed analysis of the balance sheet data for Ipca Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 25.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 25.00 Cr..
- For Reserves, as of Sep 2025, the value is 7,402.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,923.00 Cr. (Mar 2025) to 7,402.00 Cr., marking an increase of 479.00 Cr..
- For Borrowings, as of Sep 2025, the value is 1,279.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 1,363.00 Cr. (Mar 2025) to 1,279.00 Cr., marking a decrease of 84.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 3,557.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,432.00 Cr. (Mar 2025) to 3,557.00 Cr., marking an increase of 125.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 12,263.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11,744.00 Cr. (Mar 2025) to 12,263.00 Cr., marking an increase of 519.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 4,371.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,267.00 Cr. (Mar 2025) to 4,371.00 Cr., marking an increase of 104.00 Cr..
- For CWIP, as of Sep 2025, the value is 777.00 Cr.. The value appears strong and on an upward trend. It has increased from 622.00 Cr. (Mar 2025) to 777.00 Cr., marking an increase of 155.00 Cr..
- For Investments, as of Sep 2025, the value is 1,203.00 Cr.. The value appears strong and on an upward trend. It has increased from 980.00 Cr. (Mar 2025) to 1,203.00 Cr., marking an increase of 223.00 Cr..
- For Other Assets, as of Sep 2025, the value is 5,912.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,875.00 Cr. (Mar 2025) to 5,912.00 Cr., marking an increase of 37.00 Cr..
- For Total Assets, as of Sep 2025, the value is 12,263.00 Cr.. The value appears strong and on an upward trend. It has increased from 11,744.00 Cr. (Mar 2025) to 12,263.00 Cr., marking an increase of 519.00 Cr..
Notably, the Reserves (7,402.00 Cr.) exceed the Borrowings (1,279.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 140.00 | -394.00 | -573.00 | -265.00 | -173.00 | 230.00 | 403.00 | -264.00 | -806.00 | 931.00 | 0.00 | 0.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 50 | 41 | 57 | 58 | 67 | 66 | 71 | 55 | 57 | 58 | 80 | 77 |
| Inventory Days | 272 | 293 | 289 | 290 | 286 | 316 | 294 | 337 | 337 | 276 | 350 | 336 |
| Days Payable | 110 | 97 | 145 | 130 | 137 | 154 | 135 | 140 | 101 | 83 | 110 | 111 |
| Cash Conversion Cycle | 213 | 237 | 200 | 218 | 216 | 228 | 229 | 251 | 293 | 251 | 321 | 302 |
| Working Capital Days | 82 | 68 | 61 | 74 | 80 | 88 | 88 | 103 | 102 | 71 | 111 | 101 |
| ROCE % | 28% | 14% | 5% | 9% | 10% | 16% | 19% | 31% | 20% | 11% | 13% | 15% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Mid Cap Fund | 17,846,931 | 2.81 | 2593.34 | 17,749,473 | 2025-12-14 00:38:48 | 0.55% |
| Kotak Midcap Fund | 12,005,038 | 2.88 | 1744.45 | N/A | N/A | N/A |
| DSP Mid Cap Fund | 4,637,728 | 3.39 | 673.91 | 5,164,736 | 2025-12-08 06:09:34 | -10.2% |
| Nippon India Growth Mid Cap Fund | 3,100,000 | 1.07 | 450.46 | N/A | N/A | N/A |
| Kotak Large & Midcap Fund | 2,510,000 | 1.22 | 364.73 | N/A | N/A | N/A |
| HDFC Balanced Advantage Fund | 2,497,123 | 0.34 | 362.86 | N/A | N/A | N/A |
| DSP Small Cap Fund | 2,320,000 | 1.98 | 337.12 | 2,572,727 | 2025-12-08 06:09:34 | -9.82% |
| DSP Large & Mid Cap Fund | 1,950,196 | 1.65 | 283.38 | N/A | N/A | N/A |
| DSP ELSS Tax Saver Fund | 1,857,399 | 1.54 | 269.9 | 1,681,026 | 2025-12-08 06:09:34 | 10.49% |
| Axis Midcap Fund | 1,781,240 | 0.8 | 258.83 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 |
| Basic EPS (Rs.) | 35.14 | 25.82 | 18.58 | 34.85 | 45.01 |
| Diluted EPS (Rs.) | 29.08 | 21.57 | 18.58 | 34.85 | 45.01 |
| Cash EPS (Rs.) | 46.72 | 34.94 | 29.70 | 45.07 | 107.06 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 273.88 | 304.57 | 233.16 | 219.51 | 371.79 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 273.88 | 304.57 | 233.16 | 219.51 | 371.79 |
| Revenue From Operations / Share (Rs.) | 352.37 | 303.71 | 246.13 | 229.79 | 427.28 |
| PBDIT / Share (Rs.) | 71.70 | 56.99 | 41.48 | 54.23 | 126.70 |
| PBIT / Share (Rs.) | 56.02 | 42.91 | 31.17 | 45.07 | 110.21 |
| PBT / Share (Rs.) | 44.59 | 33.22 | 29.38 | 44.77 | 109.50 |
| Net Profit / Share (Rs.) | 31.04 | 20.86 | 19.39 | 35.91 | 90.57 |
| NP After MI And SOA / Share (Rs.) | 29.08 | 21.57 | 18.58 | 34.85 | 89.87 |
| PBDIT Margin (%) | 20.34 | 18.76 | 16.85 | 23.59 | 29.65 |
| PBIT Margin (%) | 15.89 | 14.12 | 12.66 | 19.61 | 25.79 |
| PBT Margin (%) | 12.65 | 10.93 | 11.93 | 19.48 | 25.62 |
| Net Profit Margin (%) | 8.80 | 6.86 | 7.87 | 15.62 | 21.19 |
| NP After MI And SOA Margin (%) | 8.25 | 7.10 | 7.54 | 15.16 | 21.03 |
| Return on Networth / Equity (%) | 10.61 | 8.64 | 8.06 | 16.09 | 24.24 |
| Return on Capital Employeed (%) | 15.15 | 12.44 | 11.59 | 18.52 | 28.48 |
| Return On Assets (%) | 6.27 | 4.93 | 5.46 | 11.57 | 18.78 |
| Long Term Debt / Equity (X) | 0.07 | 0.09 | 0.11 | 0.07 | 0.00 |
| Total Debt / Equity (X) | 0.18 | 0.21 | 0.24 | 0.14 | 0.05 |
| Asset Turnover Ratio (%) | 0.78 | 0.78 | 0.76 | 0.79 | 0.91 |
| Current Ratio (X) | 2.63 | 2.35 | 2.87 | 3.04 | 2.96 |
| Quick Ratio (X) | 1.55 | 1.30 | 1.91 | 1.77 | 1.59 |
| Inventory Turnover Ratio (X) | 3.55 | 1.05 | 0.94 | 0.95 | 1.10 |
| Dividend Payout Ratio (NP) (%) | 13.75 | 9.27 | 21.53 | 11.47 | 8.90 |
| Dividend Payout Ratio (CP) (%) | 8.93 | 5.60 | 13.84 | 9.08 | 7.52 |
| Earning Retention Ratio (%) | 86.25 | 90.73 | 78.47 | 88.53 | 91.10 |
| Cash Earning Retention Ratio (%) | 91.07 | 94.40 | 86.16 | 90.92 | 92.48 |
| Interest Coverage Ratio (X) | 21.42 | 10.46 | 23.11 | 178.91 | 177.79 |
| Interest Coverage Ratio (Post Tax) (X) | 12.69 | 5.61 | 11.80 | 119.46 | 128.08 |
| Enterprise Value (Cr.) | 40485.27 | 33899.87 | 20234.90 | 27148.88 | 24038.82 |
| EV / Net Operating Revenue (X) | 4.53 | 4.40 | 3.24 | 4.66 | 4.44 |
| EV / EBITDA (X) | 22.26 | 23.45 | 19.23 | 19.73 | 14.96 |
| MarketCap / Net Operating Revenue (X) | 4.26 | 4.08 | 3.29 | 4.62 | 4.45 |
| Retention Ratios (%) | 86.24 | 90.72 | 78.46 | 88.52 | 91.09 |
| Price / BV (X) | 5.48 | 4.96 | 3.52 | 4.90 | 5.13 |
| Price / Net Operating Revenue (X) | 4.26 | 4.08 | 3.29 | 4.62 | 4.45 |
| EarningsYield | 0.01 | 0.01 | 0.02 | 0.03 | 0.04 |
After reviewing the key financial ratios for Ipca Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 35.14. This value is within the healthy range. It has increased from 25.82 (Mar 24) to 35.14, marking an increase of 9.32.
- For Diluted EPS (Rs.), as of Mar 25, the value is 29.08. This value is within the healthy range. It has increased from 21.57 (Mar 24) to 29.08, marking an increase of 7.51.
- For Cash EPS (Rs.), as of Mar 25, the value is 46.72. This value is within the healthy range. It has increased from 34.94 (Mar 24) to 46.72, marking an increase of 11.78.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 273.88. It has decreased from 304.57 (Mar 24) to 273.88, marking a decrease of 30.69.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 273.88. It has decreased from 304.57 (Mar 24) to 273.88, marking a decrease of 30.69.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 352.37. It has increased from 303.71 (Mar 24) to 352.37, marking an increase of 48.66.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 71.70. This value is within the healthy range. It has increased from 56.99 (Mar 24) to 71.70, marking an increase of 14.71.
- For PBIT / Share (Rs.), as of Mar 25, the value is 56.02. This value is within the healthy range. It has increased from 42.91 (Mar 24) to 56.02, marking an increase of 13.11.
- For PBT / Share (Rs.), as of Mar 25, the value is 44.59. This value is within the healthy range. It has increased from 33.22 (Mar 24) to 44.59, marking an increase of 11.37.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 31.04. This value is within the healthy range. It has increased from 20.86 (Mar 24) to 31.04, marking an increase of 10.18.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 29.08. This value is within the healthy range. It has increased from 21.57 (Mar 24) to 29.08, marking an increase of 7.51.
- For PBDIT Margin (%), as of Mar 25, the value is 20.34. This value is within the healthy range. It has increased from 18.76 (Mar 24) to 20.34, marking an increase of 1.58.
- For PBIT Margin (%), as of Mar 25, the value is 15.89. This value is within the healthy range. It has increased from 14.12 (Mar 24) to 15.89, marking an increase of 1.77.
- For PBT Margin (%), as of Mar 25, the value is 12.65. This value is within the healthy range. It has increased from 10.93 (Mar 24) to 12.65, marking an increase of 1.72.
- For Net Profit Margin (%), as of Mar 25, the value is 8.80. This value is within the healthy range. It has increased from 6.86 (Mar 24) to 8.80, marking an increase of 1.94.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.25. This value is within the healthy range. It has increased from 7.10 (Mar 24) to 8.25, marking an increase of 1.15.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.61. This value is below the healthy minimum of 15. It has increased from 8.64 (Mar 24) to 10.61, marking an increase of 1.97.
- For Return on Capital Employeed (%), as of Mar 25, the value is 15.15. This value is within the healthy range. It has increased from 12.44 (Mar 24) to 15.15, marking an increase of 2.71.
- For Return On Assets (%), as of Mar 25, the value is 6.27. This value is within the healthy range. It has increased from 4.93 (Mar 24) to 6.27, marking an increase of 1.34.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.07. This value is below the healthy minimum of 0.2. It has decreased from 0.09 (Mar 24) to 0.07, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.18. This value is within the healthy range. It has decreased from 0.21 (Mar 24) to 0.18, marking a decrease of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.78. There is no change compared to the previous period (Mar 24) which recorded 0.78.
- For Current Ratio (X), as of Mar 25, the value is 2.63. This value is within the healthy range. It has increased from 2.35 (Mar 24) to 2.63, marking an increase of 0.28.
- For Quick Ratio (X), as of Mar 25, the value is 1.55. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 1.55, marking an increase of 0.25.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.55. This value is below the healthy minimum of 4. It has increased from 1.05 (Mar 24) to 3.55, marking an increase of 2.50.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 13.75. This value is below the healthy minimum of 20. It has increased from 9.27 (Mar 24) to 13.75, marking an increase of 4.48.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 8.93. This value is below the healthy minimum of 20. It has increased from 5.60 (Mar 24) to 8.93, marking an increase of 3.33.
- For Earning Retention Ratio (%), as of Mar 25, the value is 86.25. This value exceeds the healthy maximum of 70. It has decreased from 90.73 (Mar 24) to 86.25, marking a decrease of 4.48.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 91.07. This value exceeds the healthy maximum of 70. It has decreased from 94.40 (Mar 24) to 91.07, marking a decrease of 3.33.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 21.42. This value is within the healthy range. It has increased from 10.46 (Mar 24) to 21.42, marking an increase of 10.96.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 12.69. This value is within the healthy range. It has increased from 5.61 (Mar 24) to 12.69, marking an increase of 7.08.
- For Enterprise Value (Cr.), as of Mar 25, the value is 40,485.27. It has increased from 33,899.87 (Mar 24) to 40,485.27, marking an increase of 6,585.40.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.53. This value exceeds the healthy maximum of 3. It has increased from 4.40 (Mar 24) to 4.53, marking an increase of 0.13.
- For EV / EBITDA (X), as of Mar 25, the value is 22.26. This value exceeds the healthy maximum of 15. It has decreased from 23.45 (Mar 24) to 22.26, marking a decrease of 1.19.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.26. This value exceeds the healthy maximum of 3. It has increased from 4.08 (Mar 24) to 4.26, marking an increase of 0.18.
- For Retention Ratios (%), as of Mar 25, the value is 86.24. This value exceeds the healthy maximum of 70. It has decreased from 90.72 (Mar 24) to 86.24, marking a decrease of 4.48.
- For Price / BV (X), as of Mar 25, the value is 5.48. This value exceeds the healthy maximum of 3. It has increased from 4.96 (Mar 24) to 5.48, marking an increase of 0.52.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.26. This value exceeds the healthy maximum of 3. It has increased from 4.08 (Mar 24) to 4.26, marking an increase of 0.18.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ipca Laboratories Ltd:
- Net Profit Margin: 8.8%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 15.15% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.61% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 12.69
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.55
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 37.5 (Industry average Stock P/E: 47.87)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.18
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 8.8%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 48, Kandivli Industrial Estate, Kandivli (West), Mumbai Maharashtra 400067 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Premchand Godha | Executive Chairman |
| Mr. Ajit Kumar Jain | Managing Director & CFO |
| Mr. Pranay Godha | Managing Director & CEO |
| Mr. Prashant Godha | Executive Director |
| Dr.(Ms.) Swati Patankar | Independent Director |
| Dr. Narendra Mairpady | Independent Director |
| Mr. Vivek Shiralkar | Independent Director |
| Mr. Kamal Kishore Seth | Independent Director |
FAQ
What is the intrinsic value of Ipca Laboratories Ltd?
Ipca Laboratories Ltd's intrinsic value (as of 23 January 2026) is ₹1114.43 which is 23.77% lower the current market price of ₹1,462.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹37,103 Cr. market cap, FY2025-2026 high/low of ₹1,599/1,168, reserves of ₹7,402 Cr, and liabilities of ₹12,263 Cr.
What is the Market Cap of Ipca Laboratories Ltd?
The Market Cap of Ipca Laboratories Ltd is 37,103 Cr..
What is the current Stock Price of Ipca Laboratories Ltd as on 23 January 2026?
The current stock price of Ipca Laboratories Ltd as on 23 January 2026 is ₹1,462.
What is the High / Low of Ipca Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ipca Laboratories Ltd stocks is ₹1,599/1,168.
What is the Stock P/E of Ipca Laboratories Ltd?
The Stock P/E of Ipca Laboratories Ltd is 37.5.
What is the Book Value of Ipca Laboratories Ltd?
The Book Value of Ipca Laboratories Ltd is 293.
What is the Dividend Yield of Ipca Laboratories Ltd?
The Dividend Yield of Ipca Laboratories Ltd is 0.27 %.
What is the ROCE of Ipca Laboratories Ltd?
The ROCE of Ipca Laboratories Ltd is 14.7 %.
What is the ROE of Ipca Laboratories Ltd?
The ROE of Ipca Laboratories Ltd is 12.8 %.
What is the Face Value of Ipca Laboratories Ltd?
The Face Value of Ipca Laboratories Ltd is 1.00.